1,432 results match your criteria Malignant Mesothelioma Imaging

A Case Report of Hypophosphatemia Leading to the Diagnosis of Mesothelioma.

Cureus 2022 May 24;14(5):e25285. Epub 2022 May 24.

Diabetes and Endocrinology, Royal United Hospital, Bath, GBR.

Hypophosphatemia can be commonly encountered as an electrolyte imbalance and is defined as a value less than 0.8 mmol/l (2.5 mg/dl). Read More

View Article and Full-Text PDF

FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma.

Semin Nucl Med 2022 Jun 20. Epub 2022 Jun 20.

Department of Radiology, Duke University, Durham, NC; Department of Medicine, Otago Medical School, University of Otago, Dunedin, New Zealand. Electronic address:

Lung cancer is the leading cause of cancer-related mortality in the United States. Accurate staging at initial diagnosis determines appropriate treatment and is the most important predictor of survival. Since 2018, the 8th edition of the TNM staging system has been used to stage lung cancer based on local tumor extent (T), nodal involvement (N), and metastases (M). Read More

View Article and Full-Text PDF

Primary malignant pericardial mesothelioma with a survival of 2.5 years: a case report.

Transl Cancer Res 2022 May;11(5):1451-1456

Department of Respiratory and Critical Care Medicine Division, Guiqian International General Hospital, Guiyang, China.

Background: Primary malignant pericardial mesothelioma (PMPM) is a highly malignant tumor originating in the pericardium serosum with clinical manifestations presenting as constrictive pericarditis, with pericardial tamponade and heart failure. Malignant pericardial mesothelioma is rare and has a poor prognosis, with an average survival time of 6-10 months.

Case Description: Herein, we report the case of a 57-year-old female who developed chest tightness and panic for no obvious reason. Read More

View Article and Full-Text PDF

Gelatinous Pleural Fluid With Mesothelioma.

Arch Bronconeumol 2021 Aug;57(8):543

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article and Full-Text PDF

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.

Cancers (Basel) 2022 May 29;14(11). Epub 2022 May 29.

Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.

Positron emission tomography combined with x-ray computed tomography (PET-CT) is an advanced imaging modality with oncologic applications that include staging, therapy assessment, restaging, and surveillance. This six-part series of review articles provides practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. The second article of this series addresses primary thoracic malignancy and breast cancer. Read More

View Article and Full-Text PDF

EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity.

Genes Chromosomes Cancer 2022 Jun 4. Epub 2022 Jun 4.

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Mesothelioma is a rare, aggressive malignant neoplasm of mesothelial origin. A small subset of peritoneal mesothelioma is driven by recurrent gene fusions, mostly EWSR1/FUS::ATF1 fusions, with predilection for young adults. To date, only two cases of mesothelioma harboring EWSR1::YY1 fusions have been described. Read More

View Article and Full-Text PDF

Adenomatoid mesothelioma arising from the diaphragm: a case report and review of the literature.

J Med Case Rep 2022 May 30;16(1):228. Epub 2022 May 30.

Department of Gastroenterological Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Background: Adenomatoid mesothelioma is a rare subtype of malignant mesothelioma that can be confused with adenomatoid tumors, which are classified as benign. The clinical features and optimal management of adenomatoid mesothelioma have not been elucidated in the literature. In this report, we present an extremely rare case of adenomatoid mesothelioma that developed on the peritoneal surface of the diaphragm as well as a literature review of adenomatoid mesothelioma in the abdominal cavity. Read More

View Article and Full-Text PDF

Pleural mesothelioma.

Med Clin (Barc) 2022 May 27. Epub 2022 May 27.

Unidad de Medicina Pleural, Servicio de Medicina Interna, Hospital Universitari Arnau de Vilanova, IRBLleida, Universitat de Lleida, Lleida, España. Electronic address:

The diagnosis of diffuse pleural mesothelioma requires in most cases a pleural biopsy, performed either under imaging guidance (ultrasound or computed tomography) or thoracoscopy. Loss of BAP1 or MTAP expression (immunohistochemistry) and homozygous deletion of CDKN2A (fluorescence in situ hybridization) are the basic molecular markers for the diagnosis of mesothelioma. The histologic type and patient's performance status are the most important prognostic factors. Read More

View Article and Full-Text PDF

Pericardial Mesothelioma Presenting as Constrictive Pericarditis.

Cureus 2022 Apr 19;14(4):e24270. Epub 2022 Apr 19.

Cardiology, Reading Hospital Tower Health, Reading, USA.

This case report presents a 60-year-old gentleman with a significant smoking history and possible asbestos exposure who was referred to the emergency department for atrial fibrillation with a rapid ventricular rate and symptoms of heart failure. Labs showed normal brain natriuretic peptide and troponin I. His echocardiography finding suggested constrictive pericarditis with an ejection fraction of 60%. Read More

View Article and Full-Text PDF

Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients.

Cancers (Basel) 2022 Apr 30;14(9). Epub 2022 Apr 30.

Karl Landsteiner Institute for Thoracic Oncology, Klinik Floridsdorf, 1210 Vienna, Austria.

Malignant pleural mesothelioma (MPM) is a rare pleural cancer associated with asbestos exposure. According to current evidence, the combination of chemotherapy, surgery and radiotherapy improves patients' survival. However, the optimal sequence and weighting of the respective treatment modalities is unclear. Read More

View Article and Full-Text PDF

Molecular Radiotherapy with Lu-Immunoliposomes Induces Cytotoxicity in Mesothelioma Cancer Stem Cells In Vitro.

Int J Mol Sci 2022 Apr 1;23(7). Epub 2022 Apr 1.

Department of Radiology and Medical Imaging, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.

Malignant mesothelioma (MM) is a lethal tumor originating in the mesothelium with high chemotherapeutic resistance. Cancer stem cells (CSCs) persist in tumors and are critical targets responsible for tumor resistance and recurrence. The identification and characterization of CSCs may help develop effective treatment for MM. Read More

View Article and Full-Text PDF

Treatment of Patients with Malignant Peritoneal Mesothelioma.

J Clin Med 2022 Mar 29;11(7). Epub 2022 Mar 29.

Division of Surgical Oncology, Department of Surgery, The Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.

Malignant peritoneal mesothelioma is a rare malignancy arising from the serosa of the peritoneal cavity. It is diagnosed based on suspicious findings on cross sectional imaging and a tissue biopsy showing confirmatory histologic and immunohistochemical features. The disease is hallmarked by its propensity to progress mainly in the peritoneal cavity. Read More

View Article and Full-Text PDF

Intraoperative near-infrared molecular imaging for diagnostic thoracoscopy in difficult clinical scenario.

Rep Pract Oncol Radiother 2022 22;27(1):176-179. Epub 2022 Mar 22.

Department of Surgical Science, University of Turin, Turin, Italy.

Precise diagnosis in intrathoracic malignancies is paramount for adequate treatment planning. Standard approach is histologic analysis from targeted biopsy obtained with different invasive procedures. Rarely, in difficult clinical scenarios, even gold standard diagnostic procedures can be ineffective in obtaining a satisfying result. Read More

View Article and Full-Text PDF

Challenging Diagnostic Process for a Malignant Peritoneal Mesothelioma Patient With Ascites and Pleural Effusion: A Case Report and Review of the Literature.

Front Oncol 2022 15;12:784064. Epub 2022 Mar 15.

The Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

Malignant peritoneal mesothelioma (MPM) is a sporadic and fatal disease of the peritoneal lining. Its diagnosis has been known to be challenging, time-consuming, and money-consuming. In this paper, we report an MPM case of a 58-year-old man with severe abdominal distension. Read More

View Article and Full-Text PDF

A case of simultaneous diagnosis of tunica vaginalis testis and pleural mesothelioma.

Respirol Case Rep 2022 Apr 22;10(4):e0937. Epub 2022 Mar 22.

Department of Respiratory Medicine National Center for Global Health and Medicine Tokyo Japan.

A 37-year-old man was admitted to our hospital with chest pain and fever. Computed tomography showed pleural effusion and irregularly marginated, elevated lesions inside diffuse pleural thickening. Detailed medical examination showed swelling of the left testicle. Read More

View Article and Full-Text PDF

The Use of Chest Magnetic Resonance Imaging in Malignant Pleural Mesothelioma Diagnosis.

Diagnostics (Basel) 2022 Mar 19;12(3). Epub 2022 Mar 19.

Department of Diagnostic Imaging, Diagnostic Radiology 2, Pisa University Hospital, 56124 Pisa, Italy.

In recent years, many articles have demonstrated that magnetic resonance imaging (MRI) may be performed successfully in the study of the chest. The aim of this study was to evaluate the potential role of MRI in the differentiation of benign from malignant pleural disease with a special focus on malignant pleural mesothelioma and on MRI protocols. A systematic literature search was performed to find original articles about chest MRI in patients with either benign or malignant pleural disease. Read More

View Article and Full-Text PDF

Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.

Cancers (Basel) 2022 Mar 18;14(6). Epub 2022 Mar 18.

Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes, France.

Advanced hepatocellular carcinoma (HCC) is an aggressive disease associated with poor prognosis. Tumor Treating Fields (TTFields) therapy is a non-invasive, loco-regional treatment approved for glioblastoma and malignant pleural mesothelioma. HCC preclinical and abdominal simulation data, together with clinical results in other solid tumors, provide a rationale for investigating TTFields with sorafenib in this patient population. Read More

View Article and Full-Text PDF

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report.

Thorac Cancer 2022 05 21;13(9):1423-1426. Epub 2022 Mar 21.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Malignant melanoma is the most aggressive skin cancer that originates from melanocytes. Primary or metastatic pleural melanoma shares clinical and imaging characteristics with primary pleural tumors, such as pleural mesothelioma. Identification of the primary site can be challenging to distinguish between primary and secondary melanomas. Read More

View Article and Full-Text PDF

Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab.

Cureus 2022 Feb 12;14(2):e22159. Epub 2022 Feb 12.

Medicine, University of British Columbia, Vancouver, CAN.

Abscopal effect is a rare phenomenon in which treatment benefit from radiotherapy (RT) is seen outside the target field due to activation of the immune system inducing an anti-tumor effect. This phenomenon has been reported in cancer patients receiving immune checkpoint inhibitors (ICI). Here we report a case of presumed abscopal effect in malignant mesothelioma. Read More

View Article and Full-Text PDF
February 2022

The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.

Abdom Radiol (NY) 2022 05 7;47(5):1725-1740. Epub 2022 Mar 7.

Department of Radiology, University of Chicago, Chicago, IL, USA.

Purpose: Imaging of the peritoneum and related pathology is a challenge. Among peritoneal diseases, malignant peritoneal mesothelioma (MPeM) is an uncommon tumor with poor prognosis. To date, there are no specific guidelines or imaging protocols dedicated for the peritoneum and MPeM. Read More

View Article and Full-Text PDF

Mesothelioma with Nonbacterial Thrombotic Endocarditis: A Case Report.

JNMA J Nepal Med Assoc 2021 Nov 15;59(243):1170-1173. Epub 2021 Nov 15.

Department of Paediatrics and Adolescent Medicine, B. P. Koirala Institute of Health Sciences, Dharan, Nepal.

Non-bacterial thrombotic endocarditis is a rare condition characterized by noninfectious vegetation on cardiac valves which are often associated with malignancy. It often presents with features of embolism rather than cardiac failure. These are usually seen in autoimmune conditions, disseminated intravascular coagulation, malignancy of gut and lung but has also been reported in other malignancies as well. Read More

View Article and Full-Text PDF
November 2021

CT imaging of malignant peritoneal mesothelioma: A case report.

Radiol Case Rep 2022 Apr 8;17(4):1256-1260. Epub 2022 Feb 8.

Abdominal Radiologist, Department of Radiology, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

The peritoneal cavity is the second most common location for mesothelioma with only 10.5% of 10,589 mesothelioma cases reported in the United States between 1973 until 2005 and known with poor prognosis. Diagnosing malignant peritoneal mesothelioma is a challenge for many clinicians because the symptoms are often non-specific. Read More

View Article and Full-Text PDF

Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.

BMC Cancer 2022 Feb 20;22(1):191. Epub 2022 Feb 20.

Faculty of Medicine, University of Ljubljana, Korytkova ulica 2, 1000, Ljubljana, Slovenia.

Background: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to investigate the dynamic contrast-enhanced (DCE) MR parameters as predictors for progression-free (PFS) and overall survival (OS) in patients with MPM treated with cisplatin-based chemotherapy. Read More

View Article and Full-Text PDF
February 2022

Extensive intrathoracic and intraperitoneal splenosis mimicking mesothelioma: a case report.

J Med Case Rep 2022 Feb 19;16(1):73. Epub 2022 Feb 19.

Hepatology Division, Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Arnold-Heller-Straße 3, Bd. C, 24105, Kiel, Germany.

Background: Splenosis is the heterotopic autotransplantation of splenic tissue after severe splenic trauma and/or splenectomy. The epidemiology is elusive, but splenosis is frequently misdiagnosed as malignant tumors of gastrointestinal, gynecological, or hematological origin before the correct diagnosis is ultimately found. We herein report a rare case of combined, extensive intraabdominal and intrathoracic splenosis initially presenting as pleural mesothelioma. Read More

View Article and Full-Text PDF
February 2022

Cerebral metastases of malignant mesothelioma.

J Surg Case Rep 2022 Feb 6;2022(2):rjac002. Epub 2022 Feb 6.

Department of Neurological Surgery, Drexel University College of Medicine, Philadelphia, PA, USA.

Malignant pleural mesothelioma represents a rare etiology of lung cancer metastasis to the brain. Neurologically symptomatic presentations are extremely rare as these metastatic lesions are detected in the late stages of the disease. Despite many highly heterogenous treatment techniques reported in the literature, overall survival is poor. Read More

View Article and Full-Text PDF
February 2022

Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study.

Eur Radiol Exp 2022 02 8;6(1). Epub 2022 Feb 8.

Chromatin Dynamics Unit, Division on Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Background: Malignant mesothelioma (MM) is an aggressive tumor, with a poor prognosis, usually unresectable due to late diagnosis, mainly treated with chemotherapy. BoxA, a truncated form of "high mobility group box 1" (HMGB1), acting as an HMGB1 antagonist, might exert a defensive action against MM. We investigated the potential of BoxA for MM treatment using experimental 40-MHz ultrasound and optical imaging (OI) in a murine model. Read More

View Article and Full-Text PDF
February 2022

Sclerosing encapsulating peritonitis as a rare cause of intestinal obstruction after the treatment of peritoneal mesothelioma: a case report and review of the literature.

Transl Cancer Res 2021 Jun;10(6):3074-3080

Department of General Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Sclerosing encapsulating peritonitis (SEP) is a rare cause of intestinal obstruction that is characterized by a thick greyish-white fibrotic membrane encasing the small bowel. The clinical features are typically nonspecific, and they occasionally present with recurrent episodes of incomplete or complete intestinal obstruction. The etiology of SEP remains unclear, and the diagnosis is often delayed mainly due to the lack of specific symptoms. Read More

View Article and Full-Text PDF

Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria.

Thorax 2022 Feb 2. Epub 2022 Feb 2.

Glasgow Pleural Disease Unit, Queen Elizabeth University Hospital, Glasgow, UK

Background: In malignant pleural mesothelioma (MPM), complex tumour morphology results in inconsistent radiological response assessment. Promising volumetric methods require automation to be practical. We developed a fully automated Convolutional Neural Network (CNN) for this purpose, performed blinded validation and compared CNN and human response classification and survival prediction in patients treated with chemotherapy. Read More

View Article and Full-Text PDF
February 2022

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.

BMJ Open 2022 Jan 25;12(1):e057663. Epub 2022 Jan 25.

National Centre for Asbestos Related Diseases (NCARD), Institute for Respiratory Health, Perth, Western Australia, Australia.

Introduction: There is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma (DREAM) and Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (PrE0505)] combining the programmed death ligand-1 (PD-L1) inhibitor durvalumab with standard first-line chemotherapy exceeded prespecified safety and activity criteria to proceed to a phase 3 confirmatory trial to assess this combination. We present the protocol of the DREAM3R trial. Read More

View Article and Full-Text PDF
January 2022